82
Participants
Start Date
January 19, 2023
Primary Completion Date
December 1, 2024
Study Completion Date
December 23, 2024
TLL018 tablets
oral tablets administered 20 mg BID and 40 mg BID for 12 weeks
Mount Sinai, New York
Sadick Research Group, New York
DermDox, Sugarloaf
Lawrence Green, Rockville
CRCC, Charleston
CNS - Jacksonville, Jacksonville
CNS - Orlando SODO, Jacksonville
Sweet Hope Research Specialty, Inc, Hialeah
Life Clinical Trials, Coral Springs
D&H Doral Research Center LLC, Doral
Anchor Medical Research, LLC (Core Clinical Trials), Miami
Reserka Research, Miami
Altus Research, Lake Worth
Palm Beach, DeLand
ForCare Medical (CenExcel), Tampa
Cahaba, Birmingham
Dermatology Associates of Knoxville, Knoxville
Remington-Davis, Inc., Columbus
Revival Research Institute, Troy
Grekin Skin, Warren
Oakland Hills Dermatology, Auburn Hills
Integrated Clinical Trial Services, Inc, Des Moines
Minnesota Clinical Study Center, New Ulm
IMA Clinical Research, Monroe
Studies in Dermatology, LLC, Cypress
Acclaim, Sugar Land
Progressive Clinical Research Group, Inc., San Antonio
Austin Institute for Clinical Research, Pflugerville
Derm Research, Austin
Metropolis Derm, Los Angeles
Moy, Fincher, Chipps, Beverly Hills
Amicis Research Center, Northridge
Skin Surgical, San Diego
Integrative Skin, Sacramento
Metro Boston, Brighton
Lead Sponsor
Hangzhou Highlightll Pharmaceutical Co., Ltd
INDUSTRY